Mechanism of action
Temazepam enhances the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA-A receptors in the central nervous system. It binds to a specific allosteric site on the GABA-A receptor complex, located at the interface between alpha and gamma subunits, increasing the frequency of chloride channel opening in response to GABA binding.
This increased chloride conductance leads to neuronal hyperpolarization, reducing neuronal excitability and producing sedative, hypnotic, anxiolytic, muscle relaxant, and anticonvulsant effects. The hypnotic effect is most prominent at typical clinical doses. Temazepam demonstrates preferential binding to GABA-A receptors containing alpha-1 subunits, which are primarily responsible for sedation and amnesia. Unlike GABA itself, benzodiazepines do not activate the receptor directly but require GABA to be present, which provides a ceiling effect and relative safety margin compared to barbiturates.
- Temazepam undergoes direct glucuronidation without active metabolites, safer in hepatic impairment than diazepam or flurazepam
- Intermediate half-life (8-15 hours) reduces next-day sedation while maintaining sleep throughout the night
- Schedule IV controlled substance with abuse potential; avoid in patients with substance use disorder
- Paradoxical reactions (agitation, aggression) more common in elderly and children
- Abrupt discontinuation after prolonged use causes withdrawal: anxiety, tremor, seizures
- Crosses placenta and enters breast milk; pregnancy category X (former classification), associated with cleft palate risk
- Flumazenil is the reversal agent for benzodiazepine overdose but may precipitate seizures in chronic users
- Avoid in acute narrow-angle glaucoma and severe respiratory insufficiency
Indications
Temazepam is approved for the short-term treatment of insomnia, specifically for patients experiencing difficulty falling asleep, frequent nocturnal awakenings, or early morning awakening. Treatment duration should generally not exceed 7 to 10 consecutive days.
FDA-approved indication:
- Short-term management of insomnia (typically 7-10 days)
Off-label uses:
- Preoperative anxiolysis and sedation
- Anxiety disorders (not first-line; other benzodiazepines preferred)
The drug is intended for situational insomnia or transient sleep disturbances. Prolonged use beyond 2-3 weeks is not recommended due to tolerance development, dependence risk, and decreased efficacy. When insomnia persists, evaluation for underlying psychiatric or medical conditions is warranted rather than continued benzodiazepine therapy.
Pharmacokinetics
Absorption: Temazepam is well absorbed after oral administration, with peak plasma concentrations occurring approximately 1.2 to 1.6 hours after dosing. The onset of hypnotic effect typically occurs within 30 to 60 minutes. Food may delay but does not significantly reduce absorption.
Distribution: The volume of distribution is approximately 1.4 L/kg. Temazepam is highly lipophilic and crosses the blood-brain barrier readily. It is approximately 96% protein-bound in plasma, primarily to albumin. The drug crosses the placenta and is excreted in breast milk.
Metabolism: A key distinguishing feature of temazepam is its metabolic pathway. Unlike many benzodiazepines that undergo hepatic oxidation via cytochrome P450 enzymes, temazepam is metabolized primarily by direct conjugation with glucuronic acid (phase II metabolism). This produces inactive glucuronide metabolites. This conjugative pathway makes temazepam less susceptible to drug interactions and safer in patients with hepatic impairment or reduced oxidative capacity (elderly, patients on CYP450 inhibitors).
Elimination: The elimination half-life ranges from 8 to 22 hours (mean approximately 8-15 hours), classifying it as an intermediate-acting benzodiazepine. Metabolites are excreted primarily in urine. Clearance is not significantly affected by mild to moderate hepatic disease, but dose adjustment may be necessary in severe hepatic dysfunction. Renal impairment does not significantly alter elimination, though caution is advised in severe renal disease.
Adverse effects
Temazepam shares the adverse effect profile common to benzodiazepines, with CNS depression being the most prominent.
Common adverse effects:
- Drowsiness and sedation (most common, occurs in 10-20%)
- Dizziness and lightheadedness
- Headache
- Fatigue and lethargy
- Dry mouth
- Diarrhea or nausea
- Anterograde amnesia
- Confusion, especially in elderly patients
Serious adverse effects:
- Respiratory depression: Risk increases substantially when combined with other CNS depressants (opioids, alcohol, sedatives). This is a black box warning for all benzodiazepines.
- Complex sleep behaviors: Sleepwalking, sleep-driving, preparing and eating food, making phone calls, or having sex while not fully awake, with amnesia for the event
- Paradoxical reactions: Agitation, aggression, hallucinations, and behavioral disinhibition, more common in children and elderly
- Falls and fractures: Particularly in elderly patients due to sedation, ataxia, and impaired coordination
- Cognitive impairment: Memory problems and decreased concentration
- Dependence and withdrawal: Physical and psychological dependence can develop with prolonged use. Abrupt discontinuation may precipitate withdrawal syndrome (anxiety, insomnia, tremor, seizures)
Withdrawal symptoms after chronic use include rebound insomnia, anxiety, tremor, sweating, tachycardia, and in severe cases, seizures and delirium. Tapering is essential when discontinuing after prolonged therapy.
Tolerance to the hypnotic effects develops within days to weeks of continuous use, reducing efficacy and potentially leading to dose escalation.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to temazepam or other benzodiazepines
- Acute narrow-angle glaucoma (benzodiazepines may increase intraocular pressure)
- Sleep apnea syndrome or severe respiratory insufficiency (due to respiratory depression risk)
- Myasthenia gravis (may worsen muscle weakness)
- Severe hepatic insufficiency (risk of encephalopathy)
Black box warning: Concomitant use with opioids or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concurrent use for cases where alternative treatments are inadequate.
Warnings and precautions:
- Elderly patients: Increased sensitivity to benzodiazepines; higher risk of falls, cognitive impairment, and paradoxical reactions. The Beers Criteria recommend avoiding benzodiazepines in patients ≥65 years due to increased risk of cognitive impairment, delirium, falls, and fractures.
- Pregnancy (Category X): Temazepam is contraindicated in pregnancy. Benzodiazepine use in pregnancy, especially first trimester, is associated with increased risk of congenital malformations (cleft lip/palate). Use near delivery may cause floppy infant syndrome (hypotonia, respiratory depression, feeding difficulties).
- Lactation: Temazepam is excreted in breast milk. Breastfeeding is not recommended during treatment.
- Substance abuse history: Risk of abuse, misuse, and addiction. Use with caution or avoid in patients with current or past substance use disorders.
- Depression and suicidal ideation: Benzodiazepines may worsen depression. Risk of intentional overdose in depressed patients.
- Hepatic impairment: Although temazepam undergoes conjugation, severe liver disease may still impair clearance. Use lower doses.
- Renal impairment: Use with caution in severe renal disease.
- Operating machinery: Patients should not drive or operate heavy machinery until they know how temazepam affects them, and should allow adequate time (7-8 hours) for sleep before activities requiring alertness.
Drug interactions
CNS depressants (major interaction): Concomitant use of temazepam with opioids, alcohol, barbiturates, other benzodiazepines, sedating antihistamines, antipsychotics, or other sedative-hypnotics results in additive CNS depression. This significantly increases the risk of profound sedation, respiratory depression, coma, and death. If combination cannot be avoided, use the lowest effective doses and shortest duration, with close monitoring.
Moderate interactions:
- CYP enzyme inhibitors/inducers: Unlike oxidatively metabolized benzodiazepines (e.g., alprazolam, midazolam), temazepam metabolism via glucuronidation is not significantly affected by CYP450 inhibitors (ketoconazole, clarithromycin, grapefruit juice) or inducers (rifampin, carbamazepine, St. John's wort). This is a clinically important distinction.
- Probenecid: May inhibit glucuronidation and increase temazepam levels, potentially prolonging effects
- Theophylline: May reduce the sedative effects of benzodiazepines
- Digoxin: Benzodiazepines may increase digoxin levels; monitor digoxin concentrations
- Phenytoin: Benzodiazepines may increase phenytoin levels
Pharmacodynamic interactions:
- Muscle relaxants: Additive muscle relaxation effects
- Antihypertensives: Potential additive hypotensive effects
- Smoking (tobacco): May increase temazepam metabolism, potentially reducing efficacy
The relative lack of CYP450-mediated drug interactions is a key advantage of temazepam compared to other benzodiazepines, making it preferable in patients on complex medication regimens.
Clinical pearls
- Metabolic advantage: Temazepam's conjugative metabolism (rather than CYP450 oxidation) makes it a safer choice in elderly patients
TEMAZEPAM metabolism: Think Easy Metabolism—A ZEro-Pass (direct conjugation, bypasses Phase I oxidation, no active metabolites)
Practice questions
1. A 72-year-old woman with Child-Pugh class B cirrhosis presents with insomnia. She has tried sleep hygiene measures without improvement. Her medications include furosemide and spironolactone. Which benzodiazepine is the safest choice for short-term management of her insomnia?
2. A 45-year-old man has been taking temazepam 30 mg nightly for 6 months for insomnia. He abruptly stops the medication and 2 days later presents to the emergency department with tremor, anxiety, perceptual disturbances, and a generalized tonic-clonic seizure. What is the most appropriate immediate management?
3. A 28-year-old woman in her first trimester of pregnancy reports severe insomnia affecting her daily function. She asks about temazepam. Which statement best describes the pregnancy considerations for this medication?
Frequently asked questions
How does temazepam work?
Temazepam enhances the effect of GABA at GABA-A receptors by binding to the benzodiazepine site, increasing chloride channel opening frequency. This hyperpolarizes neurons and produces anxiolytic, sedative, and hypnotic effects. Unlike some benzodiazepines, it undergoes direct glucuronidation, avoiding hepatic oxidative metabolism and reducing accumulation in liver disease or elderly patients.
What are the side effects of temazepam?
Common side effects include drowsiness, dizziness, headache, and anterograde amnesia. Serious adverse effects include respiratory depression (especially with alcohol or opioids), paradoxical agitation, dependence, and withdrawal seizures with abrupt cessation. Elderly patients face increased fall risk and cognitive impairment. Rare but serious reactions include complex sleep behaviors like sleepwalking and sleep-driving.
Is temazepam a controlled substance?
Yes, temazepam is a Schedule IV controlled substance in the United States under the Controlled Substances Act. It has recognized medical use but carries potential for abuse and physical or psychological dependence. Prescribing is regulated, and it should be used short-term (typically 7-10 days) to minimize dependence risk.
Temazepam vs lorazepam—what is the difference?
Both are benzodiazepines metabolized by glucuronidation without active metabolites, making them safer in hepatic impairment. Temazepam is specifically indicated for insomnia with an intermediate half-life (8-15 hours), while lorazepam has a shorter half-life (10-20 hours) and is used for anxiety, seizures, and procedural sedation. Lorazepam is available IV/IM; temazepam is oral only.
Can you take temazepam every night?
Temazepam is approved only for short-term use (typically 7-10 days, up to 2-4 weeks maximum). Chronic nightly use increases risk of tolerance, physical dependence, and withdrawal symptoms upon discontinuation. Long-term insomnia should be managed with cognitive-behavioral therapy and addressing underlying causes rather than prolonged benzodiazepine use.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05CD07
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.